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Summary
Transcatheter aortic valve therapies are the newest estab-
lished techniques for the treatment of high risk patients af-
fected by severe symptomatic aortic valve stenosis. The
transapical approach requires a left anterolateral mini-thor-
acotomy, whereas the transfemoral method requires an ad-
equate peripheral vascular access and can be performed
fully percutaneously. Alternatively, the trans-subclavian
access has been recently proposed as a third promising ap-
proach. Depending on the technique, the fine stent-valve
positioning can be performed with or without contrast in-
jections. The transapical echo-guided stent-valve implant-
ation without angiography (the Lausanne technique) relies
entirely on transoesophageal echocardiogramme imaging
for the fine stent-valve positioning and it has been proved
that this technique prevents the onset of postoperative
contrast-related acute kidney failure. Recent published re-
ports have shown good hospital outcomes and short-term
results after transcatheter aortic valve implantation, but
there are no proven advantages in using the transfemoral
or the transapical technique. In particular, the transapical
series have a higher mean logistic Euroscore of 27–35%,
a procedural success rate above 95% and a mean 30-day
mortality between 7.5 and 17.5%, whereas the transfemoral
results show a lower logistic Euroscore of 23–25.5%, a pro-
cedural success rate above 90% and a 30-day mortality of
7–10.8%. Nevertheless, further clinical trials and long-term
results are mandatory to confirm this positive trend. Future
perspectives in transcatheter aortic valve therapies would
be the development of intravascular devices for the abla-
tion of the diseased valve leaflets and the launch of new
stent-valves with improved haemodynamic, different sizes
and smaller delivery systems.
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Introduction
Degenerative aortic valve stenosis (AS) occurs in the eld-
erly and represents the most frequent acquired heart valve
disease, with a prevalence of 4.6% in adults aged 75 years
or more. Due to the ageing population in developed coun-
tries, the amount of elderly suffering from severe sympto-
matic AS is constantly increasing and cardiologists as well
as cardiac surgeons worldwide are already facing a greater
burden from this valvular disease [1–4].
Concerning the standard treatment for symptomatic
AS, there is still a lack of pharmacological therapies to pre-
vent or slowdown the progression of this potentially life-
threatening disease and, unfortunately, percutaneous aortic
valve ballooning (valvuloplasty) has revealed questionable
short-term and mid-term results [5, 6]. Thus, this technique
is no longer considered a valid therapy for AS but is still
indicated to temporarily improve the patient’s haemody-
namic (in case of AS followed by acute cardiac decom-
pensation), or as a palliative treatment for patients not re-
ferred to open heart surgery. As a consequence, for the
last fifty years the standard open heart surgery for aortic
valve replacement (AVR) with use of cardiopulmonary by-
pass (CPB), sternotomy (or mini-sternotomy), aortic cross
clamping and cardioplegic arrest represents the treatment
of choice and the standard of care for patients carrying
severe AS with symptoms, and the mid- and long-term res-
ults are very satisfactory [7–10]. Moreover, during the last
twenty years it has been proven that the refinement of sur-
gical techniques, anaesthesiological management and in-
tensive care treatments have favourably influenced the out-
come and the surgical results of patients aged 80 years or
more, who underwent isolated AVR [11–16].
However, there is still a pool of patients affected by
severe AS requiring AVR (estimated at 33% of patients
with severe symptomatic AS) who do not undergo valve
surgery because they are considered too old (nonagenari-
ans, centenaries) for such an invasive procedure, or be-
cause they are affected by concomitant co-morbidities that
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noticeably increase the operative risk (too high risk for hos-
pital mortality and/or onset of severe postoperative com-
plications) [17]. The amount of people included in this sub-
group will likely increase constantly during the upcoming
decades because an ageing population will have more co-
morbidities and, consequently, doctors and surgeons will
deny high-risk AVRs.
In this scenario, transcatheter minimal invasive beating
heart aortic valve therapies (transcatheter aortic valve im-
plantation: TAVI) have been considered as attractive al-
ternatives to the standard AVR for patients carrying an
elevated predictable operative risk or in case of peculiar
clinical situations that could compromise the patient’s out-
come after standard open heart surgery.
Aortic stent-valves
In the 1990s, the visionary idea of implanting valved stents
in the aortic annulus stimulated basic research, computer
simulations, bench tests and animal models all over
Figure 1
The CoreValve® by Medtronic, Minneapolis, MN, for retrograde
implantations only.
Figure 2
The SapienTM THV (left) and the new Sapien XTTM generation
(right) by Edwards Lifesciences, Irvine, CA, for antegrade and
retrograde implantations.
Europe, and, at the beginning of this century (April 2002),
the first transcatheter aortic stent-valve implantation in hu-
man (using an antegrade trans-septal venous approach
through a femoral vein) was performed by Dr. Cribier in
Rouen, France [18–26].
Since then, only two different sutureless transcatheter
aortic stent-valves have been developed, tested and, subse-
quently, introduced into the current clinical practice. These
two devices, which are routinely implanted in several
highly specialised cardiac centres, are the CoreValve® sys-
tem by Medtronic, Minneapolis, MN, (fig. 1), which is
only available for a retrograde purpose, and the Edwards
Sapien™ THV stent-valve system by Edwards Lifescien-
ces INC, Irvine, CA, (fig. 2), which is available for both
the antegrade and the retrograde applications. However,
a few more devices, allowing for antegrade and/or retro-
grade implantations, have already passed the animal lab
tests and are now under human clinical investigation (see
the chapter: future perspectives).
Medtronic CoreValve®
The CoreValve® system (fig. 1) is a self-expandable nitinol
stent with an inner porcine pericardial valve, which re-
ceived the CE mark in 2007. The stent-valve is designed
to sit into the aortic root and to anchor into the aortic an-
nulus. However, the valve function is more supra-annular
and a skirt of pericardium, bordering the lower portion of
the stent-valve, prevents paravalvular leaks. The valve is
available in two sizes, the 26 mm and the 29 mm, and the
delivery system (only for retrograde applications) has an
external diameter of 18F allowing for a transfemoral (TF)
(recommended) or a trans-subclavian (off-label use) tran-
scatheter stent-valve implantation.
Edwards Sapien™ THV
The Edwards Sapien™ THV stent-valve (fig. 2) is a tube-
like stainless steel balloon-expandable stent, of 14–16 mm
in length, with an inner bovine pericardial valve treated
with the ThermaFix™ anticalcification system, that re-
ceived the CE mark approval in October and December
2007 for its transfemoral and transapical (TA) applications,
respectively. The stent-valve is inserted and deployed with-
in the aortic annulus and sits in a sub-coronary position.
The Sapien™ stent-valve is available in two sizes, a 23 mm
(14 mm length) and a 26 mm (16 mm length), and can
be introduced via a transapical (antegrade, Edwards As-
cendra™ system) or a transfemoral (retrograde, Edwards
RetroFlex™ system) transcatheter approach that requires a
22F (for the 23 mm) or a 24F (for the 26 mm) sheath.
Edwards Sapien XT™ THV
The new generation of Edwards Sapien™ THV, the XT
generation (fig. 2), was officially launched in the second
quarter of 2010. This new device, available for transapical
and transfemoral applications, has important innovations:
first of all, both the retrograde and the antegrade implant-
ation will benefit from new smaller sheaths; an 18F sheath
for transfemoral access (allowing for full percutaneous pro-
cedures) and a 22F or 24F sheath for the transapical access.
The new transfemoral delivery system is called the
NovaFlex™ system, whereas the new transapical delivery
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system is named Ascendra II™ and both are easier to use
compared to the older versions. Other important innova-
tions are the new stent (cobalt-chromium) that allows for a
smaller crimped profile with a higher resistance to mech-
anical stress, and the re-designed valve leaflets that gain a
“semi-closed” profile at rest (instead of an open profile) al-
lowing for an easier closure under pressure once implanted.
Moreover, a new 29 mm Sapien XT™ THV for transapical
applications only, will be available in 2011.
Implantation approaches
With regards to the delivery systems and their introduction
into the ascending aorta, two specific pathways have been
explored so far: the antegrade way employing direct trans-
apical access, and the retrograde way that uses either trans-
femoral or, alternatively, trans-subclavian access [27–30].
The transapical approach (TA)
The main advantages of performing transapical procedures
(fig. 3) are: i) the feasibility does not rely on the absence
of a concomitant peripheral vascular disease or previous
aortic surgery; ii) the delivery system seems to be more
“steady” and the procedure itself more “straightforward”,
and iii) this access potentially reduces the risk of calcium
dislodgment due to the passage of a stiff transfemoral
device into a diseased aortic arch. A transapical transcath-
eter aortic valve implantation (TA-TAVI) can be performed
Figure 3
Transapical approach for implanting a transcatheter aortic stent-
valve.
in the operating room, in a hybrid room, or in a cathet-
erisation laboratory with patients under general anaesthesia
(high epidural anaesthesia in a conscious patient has also
been reported). Regardless to the place where the TA is
performed, it is a prerequisite that high-quality fluoroscop-
ic imaging must be guaranteed. Apical bleeding is very
rare, mostly related to patients’ tissue fragility and/or to
the team learning curve, and represents the most danger-
ous complication related to the transapical access itself.
Once occurred, CPB resuscitation can be helpful in order
to safely repair the tear [31]. In transapical TAVI, the cardi-
ac apex is prepared through a small left anterolateral mini-
thoracotomy using a purse-string or a crossing suture rein-
forced by pledgets and, after the procedure, a chest tube is
routinely inserted into the left pleura with pain releasers in-
jected in the intercostal tissue.
The transfemoral approach (TF)
The transfemoral procedure (fig. 4) for transcatheter aortic
valve implantation (TF-TAVI) is mostly performed in the
cardiac catheterisation laboratory or in the hybrid room
and one of the main advantages of this technique is that
it allows fully percutaneous implantations in conscious pa-
tients, as long as the peripheral vessels have an adequate
caliber (more than 6 mm diameter), there are no very tortu-
ous vessels, and vascular closure devices are available. Al-
ternatively, the standard technique requires surgical prepar-
ation of the common femoral artery (rarely, the iliac artery)
Figure 4
Transfemoral approach for implanting a transcatheter aortic stent-
valve.
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under local or general anaesthesia. According to the latest
international guidelines, the presence of peripheral vascu-
lar disease, small vessel diameters, tortuous vessels, aortic
disease or previous aortic surgery contraindicates this ap-
proach. Major and minor postoperative vascular complic-
ations have been reported quite often in recent series (up
to 40% of incidence) and some critical events (vessels dis-
sections, ruptures or avulsions) might be catastrophic when
not promptly and adequately treated.
The trans-subclavian approach
Trans-subclavian access is an alternative retrograde path-
way that has been recently explored. It requires a surgical
exposure of the left subclavian artery and an adequate min-
imal vessel inner diameter for 18F delivery systems (6 mm
diameter). There are some advantages in using this ap-
proach: first of all, the distance between the site of in-
troduction and the aortic valve is short, compared to the
transfemoral option, and it results in a steadier pathway. Se-
condly, as long as the subclavian artery is intact, the trans-
subclavian procedure can be performed in case of a con-
comitant vascular disease involving the abdominal aorta or
the legs and does not require a thoracotomy. Unfortunately,
the presence of a patent internal mammary artery, such as
a diseased subclavial artery, in redo coronary surgery con-
traindicates this approach. However, at the moment this in-
teresting approach remains “off-label” and is not yet form-
ally recommended by the industry.
The trans-aortic approach
In case of severe peripheral vascular disease and a con-
comitant contraindication to transapical procedures (i.e. an
apical thrombus), an alternative, interesting, retrograde ap-
proach has been proposed: through an upper “J-shape”
mini-sternotomy, the guidewires and the delivery system
are inserted, retrogradely, into the ascending aorta and are
secured with a double purse-string suture (4-0 polypropyl-
ene). Then, the TAVI is performed as a transfemoral pro-
cedure. The presence of “porcelain” aorta and the risk of
postoperative massive bleeding limit this approach to se-
lected cases.
Patient selection and inclusion criteria
First of all, we have to state that patients suitable for TAVI
have to be selected by a multidisciplinary group of experts
composed of cardiologists and cardiac surgeons, and the
entire process requires a team approach involving an an-
aesthesiologist and doctors from the intensive care unit.
The patients’ enrolment follows the latest international
guidelines for TAVI [28]. Briefly, elderly patients with
severe symptomatic AS and a very high predictable operat-
ive risk (defined as a Logistic Euroscore-above 20% or an
STS score above 10%) are good candidates for a transcath-
eter therapeutic option. However, all cardiac centres per-
forming TAVI have already experienced the screening of
special candidates who carry a “clinically estimated” sur-
gical risk too high for standard AVR, despite the Logist-
ic Euroscore or the STS score lying below the above men-
tioned limits. In particular, a heavily calcified ascending
aorta (“porcelain” aorta), the presence of a severe congenit-
al thoracic distortion, a severe liver disease (i.e. a liver cir-
rhosis with a CHILD classification A or B), the presence
of non-cardiac tumours with a good mid-term prognos-
is or a pre-dialysis renal insufficiency, have always been
considered important risk factors contraindicating standard
AVRs with CPB. Generally speaking, we can state that all
contraindications to CPB use, sternotomy, cardioplegic car-
diac arrest or aortic cross-clamping are good indications for
a TAVI.
The native aortic annulus diameter also plays a key
role: a valve annulus measuring 19 to 25 mm diameter is
recommended for a 23 mm or a 26 mm Sapien™ THV,
whereas an aortic annulus measuring 20 to 27 mm requires
a CoreValve®. Smaller and bigger valve diameters are not
suitable, at the moment, for transcatheter valve therapies
despite the fact that, as soon as the 29 mm Sapien XT™
THV will be available, a wide 28 mm aortic annulus will
also become treatable.
A recent myocardial infarction (less than 3 months),
an extremely severe pulmonary dysfunction (avoiding thor-
acotomy and intubations), and the presence of an apical
thrombus are considered formal contraindications for trans-
apical TAVI, whereas a left ventricular ejection fraction
(LVEF) below or equal to 20% contraindicates all TAVI
procedures.
A congenitally bicuspid aortic valve is also included in
the contraindication list for TAVI, however, a successful
case of TAVI in a congenital aortic bicuspidy has recently
been published [32].
All major peripheral vascular problems involving the
aorta or the ileo-femoral arteries contraindicate transfemor-
al approaches for TAVI, but even a standard transapical
TAVI normally requires, at least, one valid peripheral ar-
terial access for the introduction of an arterial catheter (a
“pigtail” catheter) to inject contrast medium into the as-
cending aorta. However, we were able to demonstrate that
a transapical TAVI can also be successfully performed in
the absence of any valid arterial access, when the intraop-
erative angiographies are avoided and the stent-valve is po-
sitioned solely under transeosophageal echo-guidance (see
Figure 5
Image taken from the fluoroscopy system showing a transapical
valve-in-valve procedure (a 23 mm SapienTM THV into a
degenerated 23 mm Mitroflow bioprosthesis).
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the chapter: echo-guided transapical TAVI without angio-
graphy) [33].
With regard to redo aortic valve surgery, in a few ex-
perienced cardiac centres it has recently become routine
to perform “valve-in-valve” (VinV) procedures in case of
degenerated aortic bio-prostheses in high-risk patients. In
fact, the VinV strategy was developed to avoid high-risk
redo cardiac surgery in old patients with degenerated
valves, and is based on the implantation of a sized stent-
valve into the stented or stentless diseased bio-prosthesis
(the recommended minimal bio-prosthesis diameter for the
transapical implantation of an Edwards Sapien™ stent-
valve is 23 mm), and the latest postoperative clinical results
are satisfactory [34, 35] (fig. 5). However the transcatheter
VinV remains “off-label” and further clinical investigations
are recommended.
Another new approach involving transcatheter proced-
ures in case of a failed mitral valve repair is the “valve-in-
a-ring” (VinR) procedure that has been very recently pro-
posed (no clinical cases have been published yet and a case
report is under review to the Editor of the European Journal
of Cardio-Thoracic Surgery). The procedure is based on the
implantation, retrogradely, via a transapical approach, of a
stent-valve into a failed mitral repair with a ring. However
this approach is under evaluation, is an “off-label” use
and more studies are necessary to establish its feasibility
with different rings (flexible, rigid, semi-rigid) and differ-
ent sizes.
Preoperative assessment
Patients enrolled for TAVI undergo preoperative clinical
and radiological investigations in order to evaluate their
general clinical state, the size of the aortic annulus, the
presence of concomitant vascular disease and the presence
of coronary disease [36].
The standard protocol for TAVI includes the following
tests:
– thorax X-ray
– transthoracic echocardiogramme (first level of
screening)
– peripheral vascular Doppler (first level of investigation)
– transoesophageal echocardiogramme (second level)
– heart catheterisation with coronary angiogramme,
aortography and, eventually, peripheral injections.
– cardiac and vascular computed-tomography scan
followed by 3-dimentional reconstructions of the heart,
the aorta, the iliac, the femoral and, eventually, the
subclavian artery to enable measurements to be done.
Surgical techniques
Aortic stent-valve implantation with angiography
The transapical TAVI (TA-TAVI) (fig. 3) requires a left
anterolateral mini-thoracotomy through the 5th or the 6th
intercostal space. In this phase, a transthoracic echocardi-
ogramme is useful to identify the cardiac apex, in order to
place a mark on the skin. Once the pleura is opened, it is
also useful to insert a finger through it in order to identi-
fy the apex position: if the apex is easily accessible, the
procedure can be performed through this access, otherwise
the upper or the lower intercostal space can be taken in-
to consideration. After opening the pericardium, typically
two concentric purse string sutures (2-0 or 3-0 polypro-
pylene sutures with 1×0.5 cm large Teflon pledgets) have
to be prepared on the left lateral wall of the cardiac apex.
Care has to be taken in order to insert the needle through
the muscle and not through the fat in order to avoid life
threatening bleedings from ventricular tears. Once the
guidewires are passed through the apex and across the aor-
tic valve, it is important to advance them into the descend-
ing aorta using a standard pigtail catheter. Following this,
the authors immediately insert the bigger sheet (30F) which
is used to introduce the delivery system for the Edwards
SapienTM THV. Through this big sheet, we first perform the
aortic valvuloplasty and then we perform the stent-valve
implantation, both under rapid pacing (heart beat rate >180
bpm). In case of a VinV procedure, we do not perform the
Figure 6
A) angiogrammes are performed before the valve positioning in
order to assess the position of the fluoroscopic system which has to
lie perpendicular to the aortic valve plane.
B) an angiographic control performed after the stent-valve
implantation.
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valvuloplasty in order to avoid the dislodgments of valve
material.
In order to avoid parallax phenomena between the aorta
and the stent-valve during the procedure, the fluoroscopy
unit has to be precisely orientated: repeated angiographies
are performed before the balloon valvuloplasty and the
three leaflets of the aortic valve have to lie on one single
line (fig. 6A). The stent-valve positioning requires an-
giographies to verify the placement of the crimped stent-
valve is in the ideal landing zone (the stent-valve has to lie
40% on the aortic side and 60% on the ventricular side),
and, at the end of the procedure when the valve is in place,
a postoperative angiographic control is also routinely per-
formed to verify the coronary patency and the absence of
major paravalvular leaks (fig. 6B). The intraoperative TEE
is used to confirm the valve positioning, the absence of ma-
jor (>2+) paravalvular leaks as well as to verify the leaflets’
motion and integrity.
The transfemoral TAVI (TF-TAVI) (fig. 4) requires valid
femoral access or, rarely, iliac access (where an 8 mm dia-
meter vascular graft is anastomosed to the vessel). The TF
procedure requires the surgical preparation of the femoral
vessel or, since the advent of small 18F delivery systems,
it can be performed fully percutaneously. Once inserted in-
to the aorta, the guidewires are advanced and placed across
the aortic arch and through the stenosed aortic valve. Dur-
ing this retrograde pathway it is important to prevent calci-
um dislodgment from a diseased aortic wall. The position-
ing of the fluoroscopy unit follows the same rules already
described for the TA procedure and repeated angiographies
are performed. Once the valvuloplasty is performed and the
crimped stent-valve is inserted across the native valve, an
aortography is performed to confirm the positioning. In the
case of a conscious patient, the postoperative TEE control
is replaced by TTE and angiography.
The two different stented valves which are available are
deployed in two different ways: under rapid cardiac pacing
(heart beat rate >180 bpm) the SapienTM THV is expan-
ded using the rapid inflation of the inner catheter-balloon,
whereas the CoreValve® auto-expands after the removal of
the delivery system. Once the valve is in place, the deliv-
Figure 7
Preoperative CT-scan reconstruction of the aortic root. On the
upper right side, two angles indicate the positioning of the aortic
valve plane in the space and the fluoroscopy is orientated
consequently (in this case, the angles are 21 degrees left-lateral
and 16 degrees cranial).
ery system is removed and a closure system is employed in
case of a percutaneous access.
Despite disadvantages, intraoperative cardiac imaging
is crucial for a successful stent-valve implantation. A major
disadvantage, related to the use of high doses of contrast
medium for the angiographies, is the quite relevant inciden-
ce of contrast-related postoperative acute renal failure after
TAVI (up to 33%), which represents an important complic-
ation negatively affecting the patients’ outcome [37, 38].
Echo-guided transapical TAVI without angiography
Routine echo-guided transapical TAVI without angio-
graphy was proposed by our group in 2009 to prevent
contrast-related acute postoperative renal failure [39–41],
and is based on our wide experience (more than 500 pro-
cedures performed) on endovascular aorta repair (EVAR)
without angiography [42].
The technique does not differ from standard transapical
TAVI as far as the surgical details are concerned. However,
preoperative and the intraoperative cardiac imaging are pe-
culiar and technical details have already been described in
a previous report [41]. The essential steps can be briefly
summarised as follows: an injected (very low dose) cardiac
computer tomography (CT-scan) is performed preoperat-
ively to measure the annulus diameter and the distance with
the coronary ostia, and to analyse the aortic root (3-D re-
constructions). Two angles are identified, a left-lateral and
a cranial one, indicating the orientation of the aortic valve
plane in the space (fig. 7). Using these angles the fluoro-
scopy is orientated into its final position, and the use of re-
peated aortographies is no longer necessary (fig. 8). The
valve positioning is the crucial phase and is based on high-
quality TEE images acquired by experienced specialists
[43] (fig. 9). The fluoroscopy without contrast still plays a
key-role for the placement of guidewires and catheters, and
for the valve ballooning and the stent-valve balloon infla-
tion. At the end of the procedure, the haemodynamic con-
trol is assessed by TEE imaging and measurements and if
the patient is stable the coronary angiogramme and the aor-
tography are no longer performed.
Clinical results
Figure 8
A schematic view of the fluoroscopy orientation in the operating
room. The left-lateral and the cranial orientations are calculated
preoperatively using CT-scan images.
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Published results have shown satisfactory short-term out-
comes after transapical and transfemoral TAVI but, to the
best of our knowledge, there is not yet evidence that a su-
periority exists between the two techniques. Thus, it would
be of great interest to develop a three-arm, randomised,
prospective clinical trial that statistically compares the
standard AVR with the transapical and the transfemoral
TAVI.
This interesting trial has not yet been developed but,
during the last four years, some articles reporting cohorts
of TAVI patients treated in Europe and Canada have been
published and the main contents are summarised in table 1
[44–52].
What is clear and evident is that the two populations of
TF and TA patients are not comparable. In fact, the logistic
Euroscore is usually 1/3 higher in the TA groups accord-
ing to the fact that these groups suffer from a higher in-
cidence of vascular disease. Concerning hospital mortality
(30 days), the results show that the TA groups have a high-
er operative mortality compared to the TF groups, whereas
Figure 9
Image from the intraoperative transoesophageal
echocardiogramme (TEE) showing the crimped Edwards SapienTM
THV during the positioning in the ideal landing zone. Landmarks
such as the hinge point of the aortic valve leaflets and the anterior
mitral valve leaflet are identified.
Figure 10
The ATS 3F® sutureless stent-valve.
the TF groups have more incidence of postoperative stroke.
Another clear finding is that the TF procedures performed
using the Core Valve® system have a higher incidence of
pace maker implantation.
As an example of a transcatheter platform, we can share
our clinical experience: we started in 2002 with animal ex-
periments [19, 20, 22–24], and we continued in 2006 with
the first transapical stented valve (ATS 3F) implanted into
a human in Switzerland (fig. 10).
With regards to the Edwards SapienTM THV, we
launched TA implants very early in 2008 and, during a
period of 18 months, 40 transapical TAVI and 2 trans-
femoral cases (TF is still performed under proctor supervi-
sion) were performed. The mean age of the population was
81 ± 8 years, the mean logistic Euroscore was 35 ± 14.5%
(range 14–75%), and there were 24 females (60%). Special
indications included: previous thoracic radiotherapy (2 pa-
tients), porcelain aorta (3) and liver cirrhosis with oeso-
phageal varices (CHILD B classification) in 2 patients. We
also performed two VinV procedures: a 23 mm SapienTM
in 2 degenerated 23 mm bio-prosthesis (a 7 year old Mitro-
flow and a 7 year old Edwards Perimount). Three patients
were in a critical preoperative state, three had chronic ren-
al failure with a pre-dialysis state (blood creatinine level
chronically above 230, 250 and 300 µg/dl, respectively),
15 (37.5%) had chronic pulmonary disease (COPD), 30
(75%) had a peripheral vascular disease (6 patients under-
went previous vascular surgery), 21 (52.5%) suffered from
coronary disease (7 patients had previous surgery and 4
had coronary angioplasty/stenting), and 15 suffered from
chronic renal insufficiency (the mean preoperative blood
creatinine and urea levels were 108 ± 70 µg/dl and 9.2 ±
5.6 mmol/l, respectively). The mean ejection fraction was
53 ± 12%. The procedural success rate was 97.5% and we
implanted a 26 mm SapienTM THV 23 times and a 23 mm
SapienTM THV 17 times. The 30-day mortality was 7.5%
(3 patients died from severe right ventricular dysfunction,
intra-procedural left-ventricular free wall rupture and late
bilateral pneumonia) and we did not have patients with
postoperative myocardial infarction, acute renal failure (the
total mean postoperative blood creatinine and urea levels
were 91.7 ± 60 µg/dl and 7.8 ± 3.6 mmol/l, respectively),
and atrio-ventricular block. The post-procedural stroke rate
was 0% but, unfortunately, a left hemiplegia occurred in an
old lady at postoperative day 9, despite a therapy with as-
pirin (100 mg) and warfarin. The mean operative time was
108 ± 34 minutes and the postoperative recovery required
a mean intensive care unit stay of 2.2 ± 3.5 days (median:
1 day) and a mean hospital stay of 15 ± 9 days (median:
12.5 days). A total of 34 patients were rapidly extubated
and, among them, 8 patients were extubated in the oper-
ating theatre. The postoperative haemodynamic showed a
mean trans-valvular gradient of 15 ± 9 (max) and 8.7 ± 5
mm Hg (mean), with 7 patients carrying a trivial (1+/4)
paravalvular leak and 3 patients a mild (2+/4) paravalvular
leak.
To summarise, our pioneering experience on TAVI is
in line with the most-recent reports present in the literature
(see the comparison in table 1). In particular, all centres
who are familiar with this minimally invasive technique
report a mean logistic Euroscore ranging between 27 and
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35%, a procedural success rate mostly above 95% and
a mean 30-day mortality rate between 7.5 and 17.5%. If
the percutaneous transfemoral TAVI (with the two systems
available at the moment) is taken into consideration, the
published results show a lower mean logistic Euroscore
ranging between 23 and 25.5%, a procedural success rate
always above 90%, and a 30-day mortality rate around
7–10.8% [43–51].
It is remarkable that both the transapical and the trans-
femoral TAVI have a physiological learning curve and, in
some recently published reports, the cohorts of patients are
split into two groups: an earlier group (20–25 patients) that
includes the learning curve phase, and a group of patients
operated on more recently [46, 48]. In these papers, authors
have concluded that the inclusion criteria did not change
over the time and the mean logistic Euroscore remained un-
changed or even increased in the most recent series, where-
as the procedural successful rate, together with the 30-day
mortality rate, ameliorated sensibly after the learning curve
period. In our experience, we can confirm this downward
trend for hospital mortality after the physiological learning
curve phase, and we can also confirm that the surgical risk
is higher in patients that were addressed most recently to
transapical TAVI: in the first 20 cases performed in our
centre, we had an observed 30-day mortality of 10% with
a predicted operative mortality of 29% (by logistic Euro-
score), whereas, within the second 20 cases performed, we
had an amelioration in the observed 30-day mortality (5%)
despite a worst predicted surgical risk of 40% (by log. Eur-
oscore).
Nevertheless, more single- and multicentre reports with
longer follow-ups are required to confirm the good trend of
this promising transcatheter valve technology.
Future perspectives
After the CE-mark approval, the transapical and the trans-
femoral TAVI performed with the Sapien™ THV and the
CoreValve® have become routine procedures in selected
cardiac centres, allowing further hospitals to begin their
own transcatheter valve programme soon. Therefore, we
Figure 11
The stent-valve by Symetis SA, Lausanne, Switzerland.
Table 1
Comparison between the most recently published series of transapical and transfemoral transcatheter aortic valve implantations using the Edwards Sapien™ THV and the
Medtronic CoreValve®.
Study/Author Patients
(n)
Mean
age (Y)
logistic
ES (%)
STS
score (%)
Success
(%)
30-day
mortality
(%)
PM
implantation
(%)
Stroke
rate (%)
Postop. renal
failure (%)
Edwards Sapien™: transapical
Ferrari (Lausanne, Switzerland) 40 81 35 – 97.5 7.5 0 2.5 0
Ye (Vancouver, Canada) [44] 71 80 34.5 12.1 95.8 16.9 8.5 1.4 data not available
Rodés-Cabau (multicentric, Canada) [45] 177 80 – 10.5 96.1 11.3 6.2 1.7 haemodialysis: 3.4
Walther (multicentric, Germany) [46] 59 81 27 – 90 13.6 data not available 3.4 haemodialysis: 13.5
Wendt (Essen, Germany) [47] 40 82 41.6 16.5 97.5 17.5 data not available 0 12.5
Himbert (Paris, France) [48] 24 82 28 18 100 16 4 0 data not available
mean 81.00 33.22 14.28 96.15 13.80 4.68 1.50
Edwards Sapien™: transfemoral
Rodés-Cabau (multicentric, Canada) [45] 162 83 − 9 90.5 9.5 3.6 3 haemodialysis: 1.8
Himbert (Paris, France) [48] 51 82 25 15 90 8 6 6 data not available
Webb (Vancouver, Canada) [49] 113 85 25 8.7 94 8 4.4 5 4.4
mean 83.33 25.00 10.90 91.50 8.50 4.67 4.67
CoreValve® 18F: transfemoral
Grube (Siegburg, Germany) [50] 102 82 24.5 8.6 91.2 10.8 33.3 2.9 data not available
Tamburino (Catania, Italy) [51] 30 82 25.3 − 97 6.7 20 3 0
Piazza (multricentric) [52] 646 81 23 − 97.2 8 9.3 1.9 data not available
mean 81.67 24.27 8.60 95.13 8.50 20.87 2.60
Procedural success: at least one stent-valve in place, no need for full sternotomy and patient leaving alive the OR/hybrid room/cath. lab.
Data not available: the variable does not appear in the manuscript, but it does not mean that the event did not happen.
ES: Euroscore.
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will probably face a constant increase in stent-valve im-
plantations with great benefits in terms of wider clinical tri-
als and new technical/research investments.
Concerning the surgical indications, the high-risk eld-
erly patient with severe and symptomatic AS will remain
the ideal candidate for a while. However, as soon as the
overall quality and longevity of these stent-valves has been
proven by long-term follow-ups, patients carrying a lower
predictable operative risk profile might be considered as
candidates for TAVI. With regards to the technical devel-
opments, new futuristic tools that offer the opportunity
to completely ablate, percutaneously, the diseased aortic
valve leaflets before the stent-valve implantation are under
development but, to the best of our knowledge, only few
bench tests have been performed so far [53–56]. The stent-
valve evolution will also provide new stent-valves for
transapical and transfemoral applications, such as the Sy-
metis stent-valve (Symetis SA, Lausanne, Switzerland)
(fig. 11), and the Ventor Embracer™ stent-valve (Medtron-
ic, Minneapolis, MN) for an exclusive transapical use, or
the JenaClip™ stent-valve (JenaValve Technology, Mu-
nich, Germany) for both transapical and transfemoral ap-
plications [57, 58]. These new stented valves will bring
innovations such as a greater variety of sizes, expected dur-
ability (due to the employed biological tissues and their
treatment), simplicity in use (in particular for the valve po-
sitioning and implantation, and for the delivery system),
and some interesting characteristics such as the self-orient-
ation (the stent-valve leaflets will fit within the native aor-
tic valve leaflets) and the self expandability without need
for rapid cardiac pacing.
Another evolution plan is the required vessel caliber for
peripheral applications. In fact, the minimal vessel diamet-
er required for the delivery system insertion during trans-
femoral and trans-subclavian TAVI procedures will con-
tinue to decrease as long as smaller delivery systems and
smaller crimped stent-valves are developed by the industry.
However, the extreme downsizing of the crimped stent-
valve can compromise the quality of the metallic stent
(which is crimped under high compressive forces) and the
integrity of the leaflets (the thickness of the tissue em-
ployed to create valve leaflets is artificially lowered to min-
imise the size of the crimped valve).
Regarding the transapical minimal invasiveness and the
latest alternative access point, our group has already pro-
posed, in an animal model, the use of “natural orifices”,
such as the umbilicus, for transapical or transventricular
stent-valve implantations, where the delivery system is in-
troduced into the human body through a natural skin access
point [59].
More realistically, the fully percutaneous transfemoral
stent-valve implantation already exists thanks to the
downsizing of the delivery system and the flexibility of the
crimped stent-valve. However, a future perspective would
be the transapical TAVI performed under thoracoscopy,
and the development of new ventricular closure devices ap-
pears to be the most important step for a fully percutaneous
transapical procedure [60].
Conclusion
Transapical and transfemoral TAVI are the most recent es-
tablished techniques for the treatment of isolated high-risk
AS in the elderly and the latest publications have shown
satisfactory hospital outcomes and mid-term results (up to
two years). As a consequence, it can be presumed that the
indications for this disruptive procedure will expand to-
wards younger and less risky candidates as soon as ongoing
clinical trials provide supporting long-term results.
In the near future, the evolving technology will provide
new stent-valves with ameliorated designs and perform-
ance, and new smaller delivery systems allowing for less
invasive procedures and a lower risk of vascular and cardi-
ac injuries.
It should not be forgetten that the cooperation between
cardiac surgeons, cardiologists, anaesthesiologists, radiolo-
gists and technicians (the so-called teamwork or team ap-
proach) is one of the most important parts of the entire
TAVI process and its focus is the patient’s physical and
mental wellness. In conclusion, to continue to guarantee
the extraordinary and, maybe, unexpected success of this
new minimally invasive procedure, the team approach
should remain a key-point for all teams who intend to cre-
ate a new TAVI platform soon.
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